Regression of systemic lupus erythematosus after development of an acquired toll-like receptor signaling defect and antibody deficiency.

Toll-like receptor 9 (TLR-9) and TLR-7 may have a role in the production of anti-DNA and anti-RNA autoantibodies, respectively, but murine models do not clearly demonstrate their contribution to the development of systemic lupus erythematosus (SLE). Herein we describe a patient with SLE who had long-lasting remission of her autoimmune disease after development of an antibody deficiency resembling common variable immunodeficiency (CVID). After CVID had developed, anti-double-stranded DNA antibodies disappeared, although antinuclear antibodies remained positive for >10 years. In vitro studies revealed that the patient's B cells proliferated poorly and failed to differentiate into plasmablasts after stimulation of either TLR-9 or TLR-7, providing evidence for an acquired defect of the signaling pathway downstream of these TLRs. These observations suggest, although indirectly, that signaling through TLR-9 and TLR-7 is important in the pathogenesis of human SLE, and indicate that investigation of potential treatment strategies with TLR antagonists is warranted.

[1]  Uri Hershberg,et al.  T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells. , 2008, Immunity.

[2]  M. Cimmino,et al.  Is FDG-PET useful in the evaluation of steroid-resistant PMR patients? , 2008, Rheumatology.

[3]  G. Tsokos,et al.  Common variable immune deficiency (CVID) presenting as an autoimmune disease: role of memory B cells. , 2008, Autoimmunity reviews.

[4]  L. Joosten,et al.  The orchestra of Toll-like receptors and their potential role in frequently occurring rheumatic conditions. , 2008, Arthritis and rheumatism.

[5]  I. Olivieri,et al.  Cervical interspinous bursitis in active polymyalgia rheumatica , 2008, Annals of the rheumatic diseases.

[6]  Nichole E Carlson,et al.  Duration of humoral immunity to common viral and vaccine antigens. , 2007, The New England journal of medicine.

[7]  D. Isenberg,et al.  B cell depletion therapy in systemic lupus erythaematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response , 2007 .

[8]  J. Andreu,et al.  Common variable immunodeficiency in systemic lupus erythematosus. , 2007, Seminars in arthritis and rheumatism.

[9]  D. Isenberg,et al.  B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. , 2006, Arthritis and rheumatism.

[10]  J. Shupe,et al.  Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. , 2006, Immunity.

[11]  A. Lanzavecchia,et al.  Toll‐like receptor stimulation as a third signal required for activation of human naive B cells , 2006, European journal of immunology.

[12]  C. Cunningham-Rundles,et al.  TLR9 Activation Is Defective in Common Variable Immune Deficiency1 , 2006, The Journal of Immunology.

[13]  S. Akira,et al.  RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement , 2005, The Journal of experimental medicine.

[14]  S. Akira,et al.  Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus , 2005, The Journal of experimental medicine.

[15]  M. Shlomchik,et al.  Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors , 2002, Nature.

[16]  A. B. Lyons,et al.  Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. , 2000, Journal of immunological methods.

[17]  A. B. Lyons,et al.  B cell differentiation and isotype switching is related to division cycle number , 1996, The Journal of experimental medicine.

[18]  C. Salvarani,et al.  Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. , 1996, Arthritis and rheumatism.

[19]  Eren,et al.  The EUROclass trial: defining subgroups in common variable immunodeficiency. , 2008, Blood.

[20]  D. Isenberg,et al.  B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. , 2008, Annals of the rheumatic diseases.